BSR statement on the NICE appeal for the use of alternative anti-TNF
Document Actions
The British Society for Rheumatology (BSR) welcomes the announcement from the National Institute for Health and Clinical Excellence (NICE) Appeal Committee. The Appeal Committee has asked for a re-consideration of the decision not to allow patients prescription of an alternative anti-TNF, if they have experienced an inadequate response with an initial anti-TNF.
Dr Chris Deighton, Chair of the BSR Clinical Affairs Committee said; “We are pleased that the NICE Appeal Committee has recognised the large and growing data base indicating successful treatment with a second anti-TNF. We strongly believe the effect of treatment with anti-TNF for many patients with rheumatoid arthritis is substantial. We will continue to press NICE to allow this treatment to be used more widely in the disease”.
For further information contact:
Katy Lewis
klewis@rheumatology.org.uk
(020) 7842 0919